{"id":2036,"date":"2023-05-22T13:08:53","date_gmt":"2023-05-22T13:08:53","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:08:53","modified_gmt":"2026-06-26T13:08:53","slug":"inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/","title":{"rendered":"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023"},"content":{"rendered":"\n<p><strong>Montr\u00e9al, Canada \u2013 Le 22 mai 2023 \u2013&nbsp;<\/strong>Inversago Pharma Inc. (\u00ab Inversago \u00bb), un chef de file dans le d\u00e9veloppement d\u2019inhibiteurs du r\u00e9cepteur CB1 actifs \u00e0 la p\u00e9riph\u00e9rie afin de cibler des complications associ\u00e9es aux maladies m\u00e9taboliques et fibrotiques, annonce aujourd\u2019hui des r\u00e9sultats positifs d\u2019une \u00e9tude de preuve-de-concept sur le INV-202 dans un mod\u00e8le murin d\u2019asthme li\u00e9e \u00e0 l\u2019ob\u00e9sit\u00e9 lors de la conf\u00e9rence internationale 2023 de l\u2019American Thoracic Society (ATS), qui se tiendra du 19 au 24 mai 2023 \u00e0 Washington, D.C.<\/p>\n\n\n\n<p>Lors d\u2019une pr\u00e9sentation orale, Carolyn R. Morris, PhD, chercheuse facultaire, University of Vermont, Burlington, VT discutera des r\u00e9sultats d\u2019une \u00e9tude de preuve-de-concept con\u00e7ue afin de tester l\u2019efficacit\u00e9 du INV-202 dans un mod\u00e8le murin d\u2019asthme li\u00e9e \u00e0 l\u2019ob\u00e9sit\u00e9 quant aux effets directs au niveau des voies a\u00e9riennes et de la perte de poids. Le INV-202, le m\u00e9dicament candidat principal d\u2019Inversago, est un inhibiteur des r\u00e9cepteurs CB1 p\u00e9riph\u00e9riques potentiellement de nouvelle classe, d\u00e9velopp\u00e9 pour traiter les complications des troubles m\u00e9taboliques.<\/p>\n\n\n\n<p>\u00ab Les personnes asthmatiques et ob\u00e8ses ont une moins bonne qualit\u00e9 de vie, de plus grandes difficult\u00e9s \u00e0 contr\u00f4ler leur asthme et davantage d\u2019exacerbations que les personnes asthmatiques sans probl\u00e8me de surpoids, et ceci est en lien avec une inflammation des tissus adipeux et une dysfonction m\u00e9tabolique \u00bb, a d\u00e9clar\u00e9 Anne Dixon, DM, professeure de pneumologie au Larner College of Medicine, University of Vermont, dont le laboratoire a h\u00e9berg\u00e9 l\u2019\u00e9tude.<\/p>\n\n\n\n<p>\u00ab Le INV-202 est d\u00e9velopp\u00e9 pour traiter des complications li\u00e9es aux troubles m\u00e9taboliques, et ces donn\u00e9es pr\u00e9cliniques d\u00e9montrent son potentiel de cibler \u00e9galement les tr\u00e8s grands besoins non combl\u00e9s li\u00e9s au contr\u00f4le de l\u2019asthme compliqu\u00e9 par l\u2019ob\u00e9sit\u00e9 \u00bb, ajoute Glenn Crater, DM, Chef de la direction m\u00e9dicale d\u2019Inversago.<\/p>\n\n\n\n<p><strong>D\u00e9tails de la pr\u00e9sentation<\/strong><\/p>\n\n\n\n<p>Titre du r\u00e9sum\u00e9 : Cannabinoid Receptor 1 Inverse Agonist, INV-202, Induces Weight Loss and Reduces Airway Hyperreactivity in a Mouse Model of Obese Asthma [INV-202, un agoniste inverse du r\u00e9cepteur cannabino\u00efde 1, induit une perte de poids et r\u00e9duit l\u2019hyperr\u00e9activit\u00e9 des voies a\u00e9riennes dans un mod\u00e8le murin d\u2019asthme li\u00e9 \u00e0 l\u2019ob\u00e9sit\u00e9]<\/p>\n\n\n\n<p>Pr\u00e9sentatrice : Carolyn R. Morris, PhD, chercheuse facultaire, University of Vermont, Burlington, VT<\/p>\n\n\n\n<p>Session : B15 \u2013 ASTHMA: HOT OFF THE PRESS FROM THE BENCH TO THE CLINIC<\/p>\n\n\n\n<p>Date et heure : Lundi 22 mai 2023, de 9:00 \u00e0 11:00 (HE)<\/p>\n\n\n\n<p><strong>\u00c0 propos du INV-202<\/strong><\/p>\n\n\n\n<p>Le INV-202 est une petite mol\u00e9cule qui inhibe le r\u00e9cepteur CB1, d\u00e9velopp\u00e9e pour traiter potentiellement plusieurs indications cardio-m\u00e9taboliques, dont la maladie r\u00e9nale diab\u00e9tique. Elle est sp\u00e9cifiquement con\u00e7ue pour inhiber en priorit\u00e9 les r\u00e9cepteurs CB1 p\u00e9riph\u00e9riques situ\u00e9s dans les reins, le tube digestif, le foie, le pancr\u00e9as, les tissus adipeux, les muscles, les poumons et d\u2019autres organes. Les effets th\u00e9rapeutiques de l\u2019inhibition des CB1 p\u00e9riph\u00e9riques sur diverses maladies cardio-m\u00e9taboliques et fibrotiques sont bien \u00e9tudi\u00e9s et ouvrent la voie au traitement potentiel d\u2019un grand nombre de patients aux besoins actuellement non combl\u00e9s. Le INV-202 est en cours d\u2019\u00e9valuation dans une \u00e9tude de phase 2 chez des patients atteints de maladie r\u00e9nale diab\u00e9tique, dont les r\u00e9sultats sont attendus mi-2024.<\/p>\n\n\n\n<p><strong>\u00c0 propos d\u2019Inversago<\/strong><\/p>\n\n\n\n<p>Situ\u00e9e \u00e0 Montr\u00e9al (Canada), Inversago Pharma est une soci\u00e9t\u00e9 canadienne priv\u00e9e de stade clinique, leader dans le d\u00e9veloppement de th\u00e9rapies bas\u00e9es sur l\u2019inhibition des r\u00e9cepteurs CB1 p\u00e9riph\u00e9riques et con\u00e7ues pour aider les patients atteints de complications associ\u00e9es \u00e0 des maladies m\u00e9taboliques et fibrotiques. Inversago a pour ambition de procurer de nouvelles options th\u00e9rapeutiques qui am\u00e9liorent la vie de patients atteints de maladie r\u00e9nale diab\u00e9tique, incluant la n\u00e9phropathie diab\u00e9tique (ND), les diab\u00e8tes de type 1 (DT1) et de type 2 (DT2), la st\u00e9atose h\u00e9patique non alcoolique (NASH), les complications li\u00e9es \u00e0 l\u2019ob\u00e9sit\u00e9 et \u00e0 l\u2019hypertriglyc\u00e9rid\u00e9mie (HTG), ainsi que des fibroses telles que la maladie pulmonaire interstitielle fibrosante progressive (PF-ILD), incluant la fibrose pulmonaire idiopathique (FPI) et d\u2019autres conditions.&nbsp;<\/p>\n\n\n\n<p><strong>Contact<\/strong><\/p>\n\n\n\n<p>Glenn S. Vraniak<br>Chef de la direction financi\u00e8re<br>Inversago Pharma Inc.<br><a href=\"mailto:info@inversago.com\">info@inversago.com<\/a><\/p>\n\n\n\n<p><strong>M\u00e9dias et investisseurs<\/strong><\/p>\n\n\n\n<p>Argot Partners<br><a href=\"mailto:inversago@argotpartners.com\">inversago@argotpartners.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montr\u00e9al, Canada \u2013 Le 22 mai 2023 \u2013&nbsp;Inversago Pharma Inc. (\u00ab Inversago \u00bb), un chef de file dans le d\u00e9veloppement d\u2019inhibiteurs du r\u00e9cepteur CB1 actifs \u00e0 la p\u00e9riph\u00e9rie afin de [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":2031,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[114],"class_list":["post-2036","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023 | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023 | adMare\" \/>\n<meta property=\"og:description\" content=\"Montr\u00e9al, Canada \u2013 Le 22 mai 2023 \u2013&nbsp;Inversago Pharma Inc. (\u00ab Inversago \u00bb), un chef de file dans le d\u00e9veloppement d\u2019inhibiteurs du r\u00e9cepteur CB1 actifs \u00e0 la p\u00e9riph\u00e9rie afin de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-22T13:08:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:08:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/inversago-en-1684857860.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023\",\"datePublished\":\"2023-05-22T13:08:53+00:00\",\"dateModified\":\"2026-06-26T13:08:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/\"},\"wordCount\":750,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/inversago-en-1684857860.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/\",\"name\":\"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023 | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/inversago-en-1684857860.png\",\"datePublished\":\"2023-05-22T13:08:53+00:00\",\"dateModified\":\"2026-06-26T13:08:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/inversago-en-1684857860.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/inversago-en-1684857860.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023 | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023 | adMare","og_description":"Montr\u00e9al, Canada \u2013 Le 22 mai 2023 \u2013&nbsp;Inversago Pharma Inc. (\u00ab Inversago \u00bb), un chef de file dans le d\u00e9veloppement d\u2019inhibiteurs du r\u00e9cepteur CB1 actifs \u00e0 la p\u00e9riph\u00e9rie afin de [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/","og_site_name":"adMare","article_published_time":"2023-05-22T13:08:53+00:00","article_modified_time":"2026-06-26T13:08:53+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/inversago-en-1684857860.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023","datePublished":"2023-05-22T13:08:53+00:00","dateModified":"2026-06-26T13:08:53+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/"},"wordCount":750,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/inversago-en-1684857860.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/","name":"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023 | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/inversago-en-1684857860.png","datePublished":"2023-05-22T13:08:53+00:00","dateModified":"2026-06-26T13:08:53+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/inversago-en-1684857860.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/inversago-en-1684857860.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/inversago-pharma-annonce-la-presentation-de-nouvelles-donnees-lors-de-la-conference-internationale-ats-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Inversago Pharma annonce la pr\u00e9sentation de nouvelles donn\u00e9es lors de la conf\u00e9rence internationale ATS 2023"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/2036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=2036"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/2036\/revisions"}],"predecessor-version":[{"id":2037,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/2036\/revisions\/2037"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/2031"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=2036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=2036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=2036"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=2036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}